Hey Lazarus Did you catch this news?
CTD Issues Open Letter to Niemann-Pick Disease Type C Community and CTD Stakeholders
ALACHUA, FL--(Marketwired - April 10, 2017) - CTD Holdings, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease, today issued an Open Letter to address false and misleading statements, recently made by another public company, regarding CTD's hydroxypropyl beta cyclodextrin (HPBCD) product, Trappsol® Cyclo™, and its clinical use to treat Niemann-Pick Disease Type C (NPC). The false and misleading statements were made as part of another public company's announcement of their acquisition of a hydroxypropyl beta cyclodextrin product.
CTD Holdings, Inc. issues the following Open Letter to the NPC Community and CTD Holdings Stakeholders:
Dear NPC Community and CTD Holdings Stakeholders,
Many in the patient and investor communities have contacted us to ask about statements in the public domain made by another public company with a cyclodextrin product in clinical trials for NPC, VTS-270. As a result, CTD has requested that the FDA review and take appropriate action to address the false and misleading statements made about CTD's cyclodextrin product, Trappsol® Cyclo™, also in clinical trials.
The four specific misleading and inaccurate statements and CTD's factual corrections are:
(a) a statement that CTD's product is not likely to be able to be used intrathecally. In fact, Trappsol® Cyclo™ has been and currently is in use in compassionate use programs via three routes of administration -- intrathecal (IT), intravenous (IV), and intracerebral ventricular (ICV);
(b) a statement that intravenously administered versions HPBCDs do not cross the blood-brain barrier, or do so only in limited amounts. There are no formal clinical trial data showing that HPBCD does not cross the blood-brain-barrier in NPC patients.
(c) a statement that HPBCDs may only impact neurologic aspects of NPC disease when provided directly into the cerebrospinal fluid. In fact, CTD has presented data from its compassionate use program, demonstrating that IV administration has led to neurologic benefit in some patients, and
(d) an exaggerated claim regarding the use of VTS-270 in pre-clinical studies. In fact, VTS-270 did not come into existence until early 2015, when the parent company was established. The significant proportion of pre-clinical data generated to date in mice and cat models of NPC resulted from use of CTD's Trappsol® HPBCD and others, that existed in the market when the early work was conducted, not VTS-270.
We hope that this information sheds a more accurate light on the NPC clinical trials. We know that this information is accurate with respect to CTD's Trappsol® Cyclo™ product and its use. We thank the patient community for their trust and support of our programs, with special thanks to those who have used and are still using our product in compassionate use programs. Without the support from the patient community, and physicians working alongside us all, we would not be in our current position of recruiting patients into our US and EU clinical studies.
Sincerely,
N. Scott Fine
Chairman and CEO
AI
